Q-omics provides the consensus-scored SNORA20 profile across patient tissues and cancer cell-line models. SNORA20 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SNORA20 is differentially expressed in 6, with the highest sampling consensus in LIHC. Additionally, SNORA20 RNA expression shows 11,581 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where SNORA20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA20 survival associations across molecular data types. SNORA20 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA20 RNA expression–survival associations across cancer types. High SNORA20 expression shows unfavorable associations in ACC, KIRC and KICH, but favorable associations in UCS, KIRP and THYM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SNORA20 RNA expression.
This table summarizes SNORA20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA20 shows lower tumor expression in LIHC, THCA, LUSC and BRCA and higher tumor expression in COAD and BLCA. The LIHC box plot shows higher SNORA20 RNA expression in normal versus tumor tissue (log2 FC = −0.565, t-test p = .002).
This table shows molecular features associated with SNORA20 in patient tissues and cancer cell lines. In patient samples, SNORA20 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
